Categories
Change Password!
Reset Password!
Allergic rhinitis (AR) status should be considered to determine the likelihood of treatment
success of intranasal steroid (INS) for adenoid tissue hypertrophy (ATH).
As per a recent study published in American Journal of Otolaryngology, INS was found to effective for decreasing the adenoid/choana (A/C) ratio in patients with ATH with or without AR.
The health records of 96 children with established ATH were assessed to study the INS treatment outcomes in patients with ATH with or without AR. The Score for Allergic Rhinitis (SFAR) questionnaire was used to determine the AR grade of the patients and categorize them in 2 groups as: Group 1, low possibility of AR (SFAR < 9); and Group 2, high possibility of AR (SFAR ≥ 9). Mometasone furoate 100 μg/Ml when used intranasally was used for ATH treatment for a minimum of 3 months. Nasal obstruction severity and snoring was assessed via visual analog scale (VAS). A group comparison of the adenoid/choana (A/C) ratios prior to and following the therapy along with the number of patient transfer to surgery was noted.
A significant variation in the A/C ratio within the group prior to and following the therapy was observed. But, the decrease in the adenoid size was more noteworthy in Group 1 as compared to Group 2. Both groups showed considerable improvement in the VAS scores. The rate of patient transfer to surgery of Group 1 was significantly lower as compared to Group 2.
The study authors concluded, the use of INS therapy to be effective in relieving the symptoms of nasal obstruction due to reduction of A/C ratio in pediatric patients with ATH with or without AR.
American Journal of Otolaryngology
Evaluation of the intranasal steroid treatment outcomes in adenoid tissue hypertrophy with or without allergic rhinitis
Erhan Arslan et al.
Comments (0)